Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $138.3 million.

  • Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) rose 11.22% to $138.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.3 million, marking a year-over-year increase of 11.22%. This contributed to the annual value of $138.3 million for FY2025, which is 11.22% up from last year.
  • As of Q3 2025, Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $138.3 million, which was up 0.11% from $138.1 million recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $138.3 million during Q3 2025, and its lowest value of $103.8 million during Q1 2021.
  • In the last 3 years, Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $124.2 million in 2024 and averaged $120.8 million.
  • Data for Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 16.18% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $104.3 million in 2021, then increased by 1.61% to $106.0 million in 2022, then climbed by 1.35% to $107.4 million in 2023, then increased by 15.83% to $124.4 million in 2024, then grew by 11.22% to $138.3 million in 2025.
  • Its last three reported values are $138.3 million in Q3 2025, $138.1 million for Q2 2025, and $126.1 million during Q1 2025.